• By ICR Secretariat
  • Posted Thursday, October 20, 2022

GSK sets high bar with trial results for RSV vaccine


  • GSK’s vaccine for respiratory syncytial virus proved strongly effective in a large Phase 3 trial, reducing cases of lower respiratory infection in people 60 years and older by 83% when compared to those given a placebo. The U.K. drugmaker gave the results from its trial on Thursday, ahead of an infectious diseases conference next week.